Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sulphonylurea Clear all
Terminated Early Phase 1 Interventional

Glyburide vs Glucovance in the Treatment of GDM

NCT02726490
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Glyburide, Glucovance
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

NCT01794143
View directory record Official record
Conditions
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions
Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine)
Drug
Lead sponsor
GRADE Study Group
Other
Eligibility
30 Years and older
Enrollment
7,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

NCT02551874
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 23, 2026, 3:59 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Spinal Cord Injury Neuroprotection With Glyburide

NCT05426681
View directory record Official record
Conditions
Acute Spinal Cord Injury
Interventions
GlyBURIDE Oral Tablet
Drug
Lead sponsor
Francis Farhadi
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

NCT01106651
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 80 Years
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865241
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

NCT03856970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

NCT00641056
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide Once Weekly, Insulin Glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Escondido, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 23, 2026, 3:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)

NCT02460874
View directory record Official record
Conditions
Cerebral Edema, Brain Metastases
Interventions
Glyburide, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Not applicable Interventional

Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

NCT00549874
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Rosiglitazone, Glyburide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Ann Arbor, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Sep 23, 2026, 3:59 AM EDT
Withdrawn Phase 4 Interventional

Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide

NCT01947699
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Glyburide, Continuous glucose monitor
Drug · Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 23, 2026, 3:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Spinal Cord Injury Neuroprotection With Glyburide

NCT02524379
View directory record Official record
Conditions
Acute Spinal Cord Injury
Interventions
Glyburide
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

NCT00707993
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin, Glipizide
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 90 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Alexander City, Alabama • Foothill Ranch, California • Huntington Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

NCT01618162
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
44
States / cities
Anaheim, California • Garden Grove, California • La Jolla, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

NCT01762046
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glipizide, Metformin, Oral Glucose Tolerance Test
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
1,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

NCT02613897
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 23, 2026, 3:59 AM EDT
Not listed No phase listed Observational

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

NCT05161429
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 23, 2026, 3:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Genotype on CYP2C9 Drug Interactions

NCT01061112
View directory record Official record
Conditions
Healthy
Interventions
Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, Tolbutamide Inhibition - Tolbutamide & Fluconazole
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

NCT00929539
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
JTT-130, JTT-130 Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
48
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Scottsboro, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

NCT00713830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 23, 2026, 3:59 AM EDT
Not listed Not applicable Interventional

Comparison of Glucovance to Insulin for Diabetes During Pregnancy

NCT00371306
View directory record Official record
Conditions
Gestational Diabetes, Type 2 Diabetes, Pregnancy
Interventions
Insulin versus glucovance (glyburide/metformin)
Drug
Lead sponsor
Regional Obstetrical Consultants
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Sep 23, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 23, 2026, 3:59 AM EDT